Parkinson's Disease and Related Disorders Part II
Handbook of Clinical Neurology (Series Editors: Aminoff, Boller and Swaab)
- William Koller, MD, PhD, Department of Neurology, UNC-Chapel Hill, NC, USA
- Eldad Melamed, MD, Department of Neurology, Rabin Medical Center, Petaq Tiqva, Israel
Through a high-level presentation of new research regarding these diseases, this handbook will give clinicians and neuroscientists alike a better understanding of the dramatic pharmacological advances made in the management of Parkinson’s disease, and the profound observations that have altered the medical community’s approach to other degenerative disorders of the nervous system.
Practitioners, researchers, and medical personnel will gain exciting insights into recent developments that form the basis for new therapeutic strategies and management protocols for the various neurological disorders that present with Parkinsonism.
Neurologists and research neuroscientists
- Published: June 2007
- Imprint: ELSEVIER
- ISBN: 978-0-444-52893-3
Table of ContentsSection 5: Treatment of Parkinson's disease
Physical therapy in Parkinson’s disease. Neuroprotection in Parkinson’s disease: clinical trials. Levodopa. Dopamine agonists. Monoamine oxidase A and B inhibitors in Parkinson’s disease. Anticholinergic medications. Antiglutamatergic drugs in the treatment of Parkinson’s disease. Investigational drugs. The importance of patients groups and collaboration
Section 6: Complications of therapy
Motor and non-motor fluctuations. Levodopa-induced dyskinesias in Parkinson’s disease. Treatment induced mental changes in Parkinson’s disease.
Section 7 Surgical treatment
Ablative surgery for the treatment of Parkinson’s disease. Deep brain stimulation. Transplantation. Gene therapy approaches for the treatment of Parkinson’s disease.
Section 8: Other parkinsonian disease syndromes
Multiple system atrophy. Progressive supranuclear palsy. Corticobasal degeneration. Infectious basis to the pathogenesis of Parkinson’s disease. Toxic causes of Parkinson’s disease. Drug induced parkinsonism. Vascular parkinsonism. Old age and Parkinson’s disease. Other degenerative processes. Hydrocephalus and structural lesions. Calcification of the basal ganglia. Trauma and Parkinson’s disease. Psychogenic parkinsonism. Parkinsonism and dystonia. Dementia with Lewy bodies. Myoclonus and parkinsonism.